Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Totus Medicines Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units. MOSHER, ERIC PARKER is the busiest examiner, with 1 pending action.
The matching counts indicate that each pending action has a separate examiner and art-unit assignment. Counsel should coordinate scientific terminology and supporting disclosure across the portfolio while tailoring each response to its own examination record. The MOSHER matter is one individual path rather than an identified concentration of the pending work.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849949 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | MOSHER, ERIC PARKER | — |
| 18550878 | THERAPEUTIC CONJUGATES | ELENISTE, PIERRE PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18763741 | THERAPEUTIC CONJUGATES | CHANDRAKUMAR, NIZAL S | 86d overdue |
| 18550878 | THERAPEUTIC CONJUGATES | ELENISTE, PIERRE PAUL | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849949 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | MOSHER, ERIC PARKER | 1612 | §102§103§112Other | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18763741 | THERAPEUTIC CONJUGATES | CHANDRAKUMAR, NIZAL S | 1625 | DP | Final Rejection | 86d overdue | Pending | Jul 03, 2024 |
| 18550878 | THERAPEUTIC CONJUGATES | ELENISTE, PIERRE PAUL | 1622 | §102§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTotus Medicines Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Eric Parker Mosher has the most, with 1 of Totus Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
